E-LIB Suche - Ergebnisse für: Kresken, M.

1

Temocillin susceptibility in Enterobacterales with an ESBL/..:

Kresken, M. ; Pfeifer, Y. ; Werner, G.
International Journal of Antimicrobial Agents. 57 (2021) 1 - p. 106223 , 2021

Link: https://doi.org/10.1016/..

2

S2k-Leitlinie der PEG zur kalkulierten parenteralen Initial..:

Brinkmann, A. ; Röhr, A. C. ; Frey, O. R....
Der Anaesthesist. 67 (2018) 12 - p. 936-949 , 2018

Link: https://doi.org/10.1007/..

3

Antimicrobial susceptibility of bacterial isolates from pat..:

Working Party 'Antimicrobial Resistance' of the Paul-Ehrlich-Society for Chemotherapy ; Olzowy, B. ; Kresken, M....
European Journal of Clinical Microbiology & Infectious Diseases. 36 (2017) 9 - p. 1685-1690 , 2017

Link: https://doi.org/10.1007/..

4

Antibiotika-Verbrauchs-Surveillance: Ausführungen und Erläu..:

Schweickert, B. ; Kern, W.V. ; de With, K....
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 56 (2013) 7 - p. 903-912 , 2013

Link: https://doi.org/10.1007/..

5

Comparative activity of pradofloxacin and marbofloxacin aga..:

KÖRBER‐IRRGANG, B. ; WETZSTEIN, H.‐G. ; BAGEL‐TRAH, S...
Journal of Veterinary Pharmacology and Therapeutics. 35 (2012) 6 - p. 571-579 , 2012

Link: https://doi.org/10.1111/..

6

Resistance trends and in vitro activity of tigecycline and ..:

Study Group ; Kresken, M. ; Becker, K....
European Journal of Clinical Microbiology & Infectious Diseases. 30 (2011) 9 - p. 1095-1103 , 2011

Link: https://doi.org/10.1007/..

7

Susceptibility of clinical isolates of frequently encounter..:

Kresken, M. ; Leitner, E. ; Seifert, H...
European Journal of Clinical Microbiology & Infectious Diseases. 28 (2009) 8 - p. 1007-1011 , 2009

Link: https://doi.org/10.1007/..

8

Susceptibility of common aerobic pathogens to tigecycline: ..:

Kresken, M. ; Leitner, E. ; Brauers, J....
European Journal of Clinical Microbiology & Infectious Diseases. 28 (2008) 1 - p. 83-90 , 2008

Link: https://doi.org/10.1007/..

9

P666 Comparative in vitro activity of tigecycline against I..:

Kresken, M. ; Brauers, J. ; Geiss, H....
International Journal of Antimicrobial Agents. 29 (2007) - p. S158-S159 , 2007

Link: https://doi.org/10.1016/..

10

P1830 Susceptibility of Gram-positive pathogens to daptomyc..:

Kresken, M. ; Brauers, J.
International Journal of Antimicrobial Agents. 29 (2007) - p. S523-S524 , 2007

Link: https://doi.org/10.1016/..

11

Bactericidal activity of daptomycin, vancomycin, teicoplani..:

Brauers, J. ; Kresken, M. ; Menke, A....
International Journal of Antimicrobial Agents. 29 (2007) 3 - p. 322-325 , 2007

Link: https://doi.org/10.1016/..

12

P1811 In vitro activity of tigecycline against Gram-positiv..:

Kresken, M. ; Brauers, J. ; Geiss, H....
International Journal of Antimicrobial Agents. 29 (2007) - p. S517 , 2007

Link: https://doi.org/10.1016/..

13

P1831 Comparative in vitro activity of tigecycline against ..:

Kresken, M. ; Brauers, J. ; Geiss, H....
International Journal of Antimicrobial Agents. 29 (2007) - p. S524 , 2007

Link: https://doi.org/10.1016/..

14

Zeitliche Entwicklung der Antbiotikaresistenz bei klinisch ..:

Kresken, M. ; Hafner, D. ; von Rosenstiel, N.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 42 (1999) 1 - p. 17-25 , 1999

Link: https://doi.org/10.1007/..

15

Drug resistance among clinical isolates of frequently encou..:

Kresken, M. ; Hafner, D. ; the Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy
Infection. 27 (1999) S2 - p. S2-S8 , 1999

Link: https://doi.org/10.1007/..